Xiangtao Li

A team including City University of Hong Kong released TriStageHLA, which splits HLA class I epitope discovery into peptide-only screening, allele-specific binding prediction and immunogenicity prediction in sequence. On held-out immunogenicity data the immunogenicity module reached AUROC 81.4% and AUPRC 73.8%, above ImmuneApp at 70.7%/63.6% and BigMHC-IM at 60.1%/51.5%; the binding module reached AUROC 96.2% and AUPRC 95.2% on combined BA/EL evaluation. In a simulated screen over 300,000 human-proteome background peptides, the screening stage kept 82.4% of true candidate peptides while discarding 87% of background peptides.

A team including City University of Hong Kong released TriStageHLA, which splits HLA class I epitope discovery into peptide-only screening, allele-specific binding prediction and immunogenicity prediction in sequence. On held-out immunogenicity data the immunogenicity module reached AUROC 81.4% and AUPRC 73.8%, above ImmuneApp at 70.7%/63.6% and BigMHC-IM at 60.1%/51.5%; the binding module reached AUROC 96.2% and AUPRC 95.2% on combined BA/EL evaluation. In a simulated screen over 300,000 human-proteome background peptides, the screening stage kept 82.4% of true candidate peptides while discarding 87% of background peptides.